NCT04246177 2026-04-22
LEAP-012
Merck Sharp & Dohme LLC
Phase 3 Completed
Clinical Trials
3,235 trialsNCT07521852 2026-04-22
A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
TaiRx, Inc.
Phase 2 Recruiting
NCT07543510 2026-04-22
Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma
Third Affiliated Hospital, Sun Yat-Sen University
Phase NA Not yet recruiting
NCT07543783 2026-04-22
Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by TACE-HAIC
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT07544121 2026-04-22
Effect of Babao Dan Capsule Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis
Nanfang Hospital, Southern Medical University
Phase NA Not yet recruiting
NCT04145141 2026-04-21
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
National Institutes of Health Clinical Center (CC)
Active not recruiting
NCT05103904 2026-04-21
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
Emory University
Phase 2 Terminated
NCT05486572 2026-04-21
PREMIUM
VA Office of Research and Development
Phase NA Recruiting
NCT06486454 2026-04-21
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
HistoSonics, Inc.
Recruiting
NCT06860490 2026-04-21
HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
Fudan University
Phase 2 Recruiting
NCT07487402 2026-04-21
Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma
Zhejiang University
Phase EARLY_PHASE1 Not yet recruiting
NCT01899261 2026-04-20
Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Montefiore Medical Center
Phase NA Completed
NCT02174549 2026-04-20
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Teclison Ltd.
Phase 1/2 Recruiting
NCT03655002 2026-04-20
IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT03942328 2026-04-20
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Mayo Clinic
Phase 1/2 Recruiting
NCT04605731 2026-04-20
Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT05208762 2026-04-20
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen Inc.
Phase 1 Recruiting
NCT06066138 2026-04-20
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT07227012 2026-04-20
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Pfizer
Phase 1/2 Recruiting
NCT07538882 2026-04-20
AI-Assisted Staging and Treatment Decision-Making for Hepatocellular Carcinoma
Beijing Tsinghua Chang Gung Hospital
Recruiting
NCT05332496 2026-04-17
CHANCE2202
Zhongda Hospital
Completed
NCT05332821 2026-04-17
CHANCE2201
Zhongda Hospital
Completed
NCT05775159 2026-04-17
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
AstraZeneca
Phase 2 Recruiting
NCT06233981 2026-04-17
Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT06427941 2026-04-17
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07391670 2026-04-17
IMFINZI-subQ
AstraZeneca
Phase 1 Recruiting
NCT07535840 2026-04-17
A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma
Tongji Hospital
Phase NA Not yet recruiting
NCT07537777 2026-04-17
Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
Nanfang Hospital, Southern Medical University
Phase 2 Not yet recruiting
NCT07537946 2026-04-17
Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
Tongji Hospital
Phase 3 Not yet recruiting
NCT07537959 2026-04-17
Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases
Tongji Hospital
Phase NA Not yet recruiting
NCT07537972 2026-04-17
Denosumab Strategy for Liver Cancer With Bone Metastases
Tongji Hospital
Phase 2 Not yet recruiting
NCT02626312 2026-04-16
Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03259867 2026-04-16
TATE-PD1
Teclison Ltd.
Phase 2 Recruiting
NCT05623150 2026-04-16
CHALNA2
Institut National de la Santé Et de la Recherche Médicale, France
Recruiting
NCT05842174 2026-04-16
TAQE
VA Office of Research and Development
Phase 1/2 Recruiting
NCT07223424 2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2 Recruiting
NCT07476651 2026-04-16
LASER
Seoul National University Hospital
Phase NA Recruiting
NCT07490262 2026-04-16
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase 2/3 Recruiting
NCT03778957 2026-04-15
EMERALD-1
AstraZeneca
Phase 3 Active not recruiting
NCT04785534 2026-04-15
Surveys, Blood Testing, and Fibroscan in Screening for Liver Fibrosis and Liver Cirrhosis
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT05143619 2026-04-15
Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines
M.D. Anderson Cancer Center
Recruiting
NCT05394259 2026-04-15
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06764316 2026-04-15
BANTAM-01
Bayer
Phase 1 Recruiting
NCT06968195 2026-04-15
Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma
Roswell Park Cancer Institute
Phase 1 Suspended
NCT03520660 2026-04-14
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
National Institutes of Health Clinical Center (CC)
Phase 4 Active not recruiting
NCT05435014 2026-04-14
T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma
T-ACE Medical Co., Ltd
Phase 1/2 Suspended
NCT06880523 2026-04-14
SLIDE-HCC
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT07164313 2026-04-14
A Study of ZW251 in Participants With Advanced Solid Tumors
Zymeworks BC Inc.
Phase 1 Recruiting
NCT07291076 2026-04-14
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting